An advisory panel working with the U.S. Food and Drug Administration has voted to reject a proposed drug from Solvay Pharmaceuticals that targets irregular heartbeat.

While the committee’s vote is not binding, it could impact the FDA’s review of Solvay’s new-drug application. The committee requested more information about the drug, called tedisamil, and the company said it will cooperate.

A decision by the FDA is expected in January. Solvay filed its application a year ago.

The committee vote was announced Wednesday.

Tedisamil targets atrial fibrillation.